Equities

Clinigen Group PLC

Clinigen Group PLC

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (GBX)993.00
  • Today's Change14.00 / 1.43%
  • Shares traded212.48k
  • 1 Year change9.85%
  • Beta0.7753
Data delayed at least 20 minutes, as of Jul 18 2018 16:52 BST.
More ▼

Key statistics

On Wednesday, Clinigen Group PLC (CLIN:LSE) closed at 993.00, 20.80% above the 52 week low of 822.00 set on May 17, 2018.
52-week range
Today
822.00May 17 20181,187.00Nov 01 2017
Markit short selling activity
Low
Med
High
Open978.50
High1,001.00
Low978.00
Bid--
Offer--
Previous close979.00
Average volume213.98k
Shares outstanding122.29m
Free float111.11m
P/E (TTM)88.02
Market cap1.20bn GBP
EPS (TTM)0.1112
GBP
Annual div (ADY)5.16
GBX
Annual div yield (ADY)0.53%
Div ex-dateMar 22 2018
Div pay-dateApr 12 2018
Data delayed at least 20 minutes, as of Jul 18 2018 16:52 BST.
More ▼

Investors Chronicle View

The last IC recommendation on Clinigen Group PLC shares was Buy at 998.00 on 18 Jul 2018Read the full article
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.